Partner with AK Medical: Orthopedic Product and Technology Partnership Opportunities
An overview of AK Medical's international footprint, product portfolio, manufacturing infrastructure, and how prospective distributors and partners can start a partnership discussion.
An orthopedic partnership is more than a purchasing relationship. For implantable medical devices, market development depends on manufacturing capability, portfolio breadth, technology platforms, regulatory status, product education, instrumentation, and the ability to support a professional clinical market over time. Before discussing commercial terms, there is a more fundamental set of questions: who develops the products, who manufactures them, which areas of orthopedic reconstruction does the portfolio address, and what international infrastructure already supports the business?
AK Medical at a glance
AK Medical Holdings Limited was founded in 2003 and listed on the Main Board of the Hong Kong Stock Exchange in 2017 under stock code 01789.HK. AK Medical describes itself as an international orthopedic group integrating research and development, product development, large-scale manufacturing, and professional marketing.
| Publicly reported information | AK Medical |
|---|---|
| Founded | 2003 |
| Hong Kong listing | 2017 |
| Stock code | 01789.HK |
| Healthcare institutions served | 7,500+ |
| Cumulative implant volume | 1.2 million+ |
| Countries and regions | 40+ |
| 3D-printing-related patents | 210+ |
| R&D centers | Beijing, Shanghai, United Kingdom |
| Manufacturing bases | Beijing Changping, Changzhou, Sheffield |
A portfolio across six clinical areas
AK Medical organizes its public product and technology portfolio into six principal areas: Hip, Knee, Spine and Trauma, Tumor, Digital Orthopedics, and ICOS™ (Innovative Customized Orthopedic Solution).
Within hip reconstruction, AK Medical publicly presents products for primary replacement, cemented reconstruction, and revision applications. Its knee portfolio includes unicompartmental knee arthroplasty, primary total knee systems, revision systems, and hinged reconstruction options. Its tumor portfolio addresses reconstruction following bone tumor resection, major bone loss, complex deformity, and selected revision scenarios. Product availability, indications, configurations, and regulatory status remain market-specific and should be confirmed for each product and jurisdiction.
Different reconstruction challenges, different implant strategies
A broad portfolio has clinical relevance only when individual products are designed around different reconstruction challenges:
- The AK-MP-TP Cementless Femoral Stem is a cementless hip stem platform, with preoperative planning around leg-length discrepancy, acetabular component position, femoral component sizing, fit, and offset, in standard and high-offset options.
- The AK-SL Femoral Stem is a titanium alloy stem designed for cementless fixation in femoral revision surgery — a 2° tapered stem, circular cross-section, eight longitudinal ribs, 190 mm and 225 mm stem-length options, and 16 sizes in total — for selected revision scenarios involving proximal femoral bone loss, periprosthetic fracture, or anatomy where proximal fixation is difficult.
- The AK-SR Total Hip System introduces an independent neck-and-sleeve arrangement designed to allow adjustment of version and address selected proximal-distal anatomical mismatch situations.
Different clinical problems are addressed through different implant concepts rather than a single universal stem philosophy. Clinical use should always follow applicable product labeling, indications, contraindications, and Instructions for Use in the relevant market.
3DACT™ additive manufacturing technology platform
AK Medical identifies 3DACT™ (also written 3D ACT™) as its additive-manufacturing technology platform, applied to orthopedic implants across joint replacement, spine, and trauma. Its 3D-printed hip cup was the first 3D-printed orthopedic implant approved in China, in 2015. The company reports more than 210 patents related to 3D-printing technology. Additive manufacturing is used across porous acetabular components, augments, bone-defect reconstruction components, and other selected implants — for example, the AK-AC-II-TTM-I Acetabular Cup incorporates a trabecular metal structure intended to provide high friction and a porous architecture for tissue ingrowth. For distributors and healthcare organizations, "3D printed" should not be treated as a substitute for product-level evaluation — material, porous architecture, mechanical characteristics, clinical evidence, indications, and regulatory status should be reviewed at the level of the specific implant.
ICOS™ customized orthopedic solutions
Most orthopedic procedures can be addressed with standard implants — some complex reconstructions cannot. AK Medical presents ICOS™ as a platform involving one-to-one interaction between engineers and physicians, customized implant design, patient matching, medical-engineering interaction, and preoperative planning, extending the portfolio into selected patient-specific reconstruction workflows for complex tumor reconstruction and severe bone-defect management. Customized and patient-specific devices are subject to jurisdiction-specific regulatory requirements, and their availability must be evaluated for the relevant country, product, and case.
Digital Orthopedics
AK Medical lists Digital Orthopedics as a dedicated product area and identifies One Point™ as a navigation and robotic intelligence technology platform, with materials referencing imaging, image processing, three-dimensional reconstruction, real-time tracking, digital planning, and selected surgical-assistance applications, including its VTS digital application. Digital product functionality, compatible implant systems, indications, regulatory status, and commercial availability should be confirmed for each individual market.
International R&D and manufacturing footprint
AK Medical lists R&D centers in Beijing, Shanghai, and the United Kingdom, and manufacturing bases in Beijing Changping, Changzhou (Jiangsu), and Sheffield (United Kingdom). The group structure also includes AK Medical, ITI Medical, JRI Orthopaedics, Libeier, and other operating entities. ITI Medical was established as a manufacturing base for AK Medical products and instruments, while the acquisition of Libeier expanded the group's presence in spine and trauma.
JRI Orthopaedics
A significant step in AK Medical's international development took place in 2018, when JRI Orthopaedics joined the AK Medical group. JRI was founded in the United Kingdom in 1969 and is associated with the development and clinical history of hydroxyapatite-coated orthopedic implants. AK Medical states that adding JRI strengthened international collaboration, global orthopedic product development, and exchange in orthopedic clinical technologies. AK Medical today continues to list R&D and manufacturing operations in the UK, including its manufacturing presence in Sheffield.
International collaboration in practice
In November 2024, a six-member delegation led by the President of ADDLIFE — described by AK Medical as a key business partner of JRI in the European market — visited AK Medical. Discussions covered orthopedic 3D-printing technology, medical-engineering collaboration, and intelligent orthopedic surgical equipment. This is a publicly documented example of international business interaction within the AK Medical and JRI network; it should not be interpreted as representing a universal distribution structure for other countries — commercial arrangements remain specific to each market and partner.
AK Academy and professional education
AK Medical established AK Academy in 2012, described as an orthopedic education and training platform serving medical professionals and other relevant stakeholders. According to AK Medical, the Academy has organized hundreds of academic activities involving orthopedic theory, surgical techniques, and clinical case discussion, in formats including professional courses, workshops, seminars, expert lectures, and international academic exchange, including interaction with institutions in the United Kingdom. The availability, scope, format, and commercial terms of market-specific education should be discussed directly with AK Medical.
Regulatory status must be confirmed at product level
By the end of 2022, AK Medical publicly reported more than 600 patents in China and overseas markets, more than 70 NMPA Class III product registrations, and more than 20 product registrations in the United States, Europe, and other countries and regions. These figures demonstrate regulatory activity across multiple markets — they do not mean every AK Medical product is registered or commercially available in every country. Before proceeding with registration, marketing, tendering, procurement, or commercial planning, prospective partners should confirm the exact product and model, component configuration, current regulatory status, approved indications, applicable Instructions for Use, and commercial availability in the relevant jurisdiction. The right question is not "does AK Medical have FDA or CE products?" — it is "what is the current regulatory status of this specific product in this specific market?"
Starting a partnership discussion
Companies interested in exploring a potential relationship with AK Medical can contact the international business team directly. To make an initial discussion more productive, prospective partners may wish to provide:
- Company name and country
- Current medical-device or orthopedic portfolio
- Product areas of interest
- Target territory
- Hospital and surgeon coverage
- Medical-device registration experience
- Tender or procurement experience
- Clinical or technical support capabilities
- Relevant market background
Distribution rights, territory arrangements, exclusivity, pricing, regulatory responsibilities, sales targets, inventory, instrumentation, training, marketing support, and other commercial terms are subject to market-specific evaluation and a final written agreement between AK Medical and the relevant business partner. No such terms should be inferred from this article.
Frequently asked questions
How can I contact AK Medical about a potential distribution partnership? Prospective partners can contact AK Medical through its international sales email at sales@ak-medical.net or its official WhatsApp number at +86 150 0110 2275.
Does AK Medical offer exclusive distribution? There is no single global exclusivity policy applicable to every market. Distribution structures and territory arrangements are market-specific and should be discussed directly with AK Medical.
Does AK Medical have international market experience? Yes — its products have been used in more than 7,500 healthcare institutions across over 40 countries and regions, with cumulative implantation exceeding 1.2 million cases, supported by R&D and manufacturing operations in both China and the United Kingdom.
Are all AK Medical products registered in the same countries? No. Regulatory status, indications, configurations, and commercial availability should be confirmed for the individual product and jurisdiction.
Contact AK Medical
International Sales: sales@ak-medical.net Official WhatsApp: +86 150 0110 2275
AK Medical also publishes contact information for its group companies, including Beijing AK Medical, ITI Medical, JRI Orthopaedics, and Libeier.
This article is intended to provide information about AK Medical's publicly disclosed corporate background, product areas, technology platforms, and international infrastructure. Product indications, contraindications, configurations, regulatory status, and commercial availability may vary by country or region. Distribution territory, commercial pricing, exclusivity, registration responsibilities, sales commitments, instrumentation, training, and marketing support are subject to a separate written agreement between AK Medical and the relevant business partner.
